Indeed, lower thromboembolic rates were observed in obese versus normal BMI AF patients in the ROCKET AF,7 ARISTOTLE,8 ENGAGE AF‐TIMI 48,9 RE‐LY,12 and AMADEUS trial (which investigated the unapproved factor Xa inhibitor idraparinux),14 whereas higher stroke/SE risks were observed in underweight AF patients (BMI <18.5 kg/m2) included in the ENGAGE AF‐TIMI 48 trial9 (not reported in other RCTs). Here, F10 is linked to Stroke.